12 | MD Anderson Cancer Center Skip to Content
Top

BY Scott Merville

Combination immunotherapy is producing response rates ranging from 26 to 38% among patients with metastatic bladder cancer in a clinical trial led by MD Anderson Cancer Center.

“Until the first, recent approval of immune checkpoint therapy, patients with bladder cancer have not had new treatment options for over 30 years. We’re quickly moving from immune checkpoint monotherapy to immune checkpoint combination therapies to improve...

bladder cancer combination immunotherapy treatment clinical trial

BY Scott Merville

The largest analysis of metastatic melanoma patients who received a targeted therapy combination shows the treatment provides long-term survival...

BY MD Anderson staff

A new trial underway at MD Anderson may lead to new therapies for triple negative breast cancer.

Fifteen to 20% of breast cancers...

BY Ron Gilmore

Patients who’ve been successfully treated for breast, colon and other cancers can go on to develop an often-fatal form of leukemia, sometimes years after completion of treatment, due to a genetic mutation leading to secondary malignancies known as therapy-related myeloid neoplasms (t-MNs).

A study conducted by researchers at MD Anderson Cancer Center revealed pre-leukemic mutations, called clonal hematopoiesis, may predict...

therapy-related myeloid neoplasms leukemia

BY Scott Merville

When female employees of a mystery shopping firm called posing as 17-year-olds interested in tanning, 81% of indoor tanning facilities complied...

BY Julie Penne

The University of Texas Health Science Center at San Antonio and The University of Texas MD Anderson Cancer Center are announcing...

BY Clayton Boldt, Ph.D.

Three years ago, Stephen Cadmus faced a dilemma. He needed to see a doctor, but he had no health insurance.

To get the medical...